0
0
Read Time:3 Minute, 51 Second
Meticulous Research®, a leading market research firm, has published a new report titled IVD Assay Development Market Size, Share, Forecast, & Trends Analysis by Offering (Assay Development, Packaging Development), Technology (Immunoassay, Molecular Diagnostics, Biochemistry), Application (Oncology, Diabetes) – Global Forecast to 2031. According to the findings, the global IVD assay development market is projected to reach $8.39 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.
Download Research Report Sample @ https://www.meticulousresearch.com/download-sample-report/cp_id=6037
The growth of the IVD assay development market is driven by the increasing prevalence of chronic diseases, a rising geriatric population, the high burden of infectious diseases, and a growing emphasis on the development of point-of-care (POC) IVD assays. Additionally, increasing healthcare expenditures are fueling the demand for more advanced diagnostic solutions. However, the evolving regulatory landscape remains a key challenge to the market’s growth.
Furthermore, emerging economies and advancements in IVD assay technologies present significant growth opportunities for market participants. Challenges related to maintaining product quality and safeguarding proprietary information also pose potential obstacles to market expansion.
Key Players:
The key players profiled in the IVD assay development market report are Thermo Fisher Scientific Inc. (U.S.), Avioq, Inc. (U.S.), Creative Biolabs, Inc (U.S.), Maxim Biomedical, Inc. (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), PeploBio Ltd (U.K.), ICON plc (Ireland), NeoDx Biotech Labs Pvt. Ltd. (India), Eclevar Medtech (France), Savyon Diagnostics (Israel), Promega Corporation (U.S.), and Future Diagnostics Solutions B.V. (Netherlands). The market is segmented by offering, technology, and application. The report also provides a comprehensive analysis of market competitors and regional trends.
Browse in depth @ https://www.meticulousresearch.com/product/ivd-assay-development-market-6037
Market Segmentation:
- By Offering: In 2024, the IVD assay development services segment is expected to hold the largest share, accounting for 45.1% of the market. This segment encompasses various stages of assay development, including raw material selection, feasibility studies, optimization of assay parameters, and clinical sample testing. The demand for IVD assays in drug discovery, particularly in assessing pharmaceutical candidates and detecting biomarkers, is driving the need for these services. As personalized medicine and precision therapies become more widespread, the demand for high-quality, customized IVD assays continues to rise, further strengthening this segment’s position.
- By Technology: The immunoassay/immunochemistry segment is projected to dominate the IVD assay development market in 2024, capturing a share of 42.3%. Immunoassay technologies leverage antigen-antibody reactions to detect causative agents, offering high specificity and throughput. The growing use of immunoassays in point-of-care (PoC) testing for infectious diseases and the increasing global demand for novel assays are driving the segment’s growth. The aging population and the continued innovation in immunoassay formats are additional factors contributing to the dominance of this technology.
- By Application: The infectious diseases application segment is anticipated to hold the largest market share in 2024. The rapid spread of infectious diseases makes accurate and early diagnosis crucial to preventing transmission. IVD assays have proven to be essential tools in diagnosing infectious diseases, driving demand for these diagnostic products. Government initiatives, advancements in diagnostic techniques, and recent global outbreaks have heightened awareness and spurred investment in diagnostic solutions. For instance, the World Health Organization (WHO) reported nearly 40 million cases of HIV globally at the end of 2023, up from 25.6 million cases in 2021, further underscoring the need for robust diagnostic tools.
Request Customization Report @ https://www.meticulousresearch.com/request-customization/cp_id=6037
Regional Insights:
The report also provides a detailed regional analysis, highlighting key markets such as North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
- By Region: North America is expected to dominate the IVD assay development market in 2024, with a share of 37.8%. This dominance can be attributed to favorable government investments in disease prevention and investigation, a high prevalence of infectious and chronic diseases, a well-established healthcare infrastructure, and a high degree of awareness regarding early disease diagnosis. Furthermore, North America’s early adoption of advanced diagnostic technologies and its strong base of key industry players contribute significantly to the region’s market leadership.
Overall, the IVD assay development market is poised for significant growth, driven by advancements in diagnostic technology, increased healthcare spending, and rising demand for early and accurate disease detection. The report offers valuable insights for stakeholders looking to capitalize on the opportunities in this evolving market.
Download Research Report Sample @ https://www.meticulousresearch.com/download-sample-report/cp_id=6037
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %